State Street® SPDR® S&P® Biotech ETF (XBI) is a SPDR ETF with a 0.35% expense ratio, 164 holdings and $10.5B in net assets. Largest sector: Healthcare (99%).
Fee
0.35%
expense ratio
Net assets
$10.5B
Launched
Jan 31, 2006
Holdings
164
as of Oct 22, 2026
Top 10 weight
17.6%
largest ten holdings
Largest sector
Healthcare
99.5%
Yield
30-day SEC -0.15% · TTM 0.36%
as of Oct 22, 2026
Benchmark
S&P Biotechnology Select Industry Index
XBI's holdings are as of Oct 22, 2026.
Healthcare
99.5%
Financial Services
0.5%
1
MRNA
MODERNA
2.23%
2
NTRA
Natera
1.81%
3
BIIB
BIOGEN
1.80%
4
HALO
Halozyme Therapeutics
1.73%
5
UTHR
United Therapeutics
1.72%
6
AMGN
AMGEN
1.71%
7
ABBV
ABBVIE
1.70%
8
EXEL
Exelixis
1.67%
9
GILD
GILEAD SCIENCES
1.61%
10
IOVA
Iovance Biotherapeutics
1.61%
11
TWST
TWIST BIOSCIENCE
1.61%
12
SYRE
Spyre Therapeutics
1.59%
13
VRTX
VERTEX PHARMACEUTICALS
1.53%
14
REGN
REGENERON PHARMACEUTICALS
1.51%
15
ALKS
Alkermes
1.45%
16
TGTX
TG Therapeutics
1.45%
17
PTGX
Protagonist Therapeutics
1.43%
18
INCY
INCYTE
1.39%
19
PTCT
PTC Therapeutics
1.39%
20
NBIX
Neurocrine Biosciences
1.38%
21
KRYS
Krystal Biotech
1.37%
22
CRSP
CRISPR THERAPEUTICS AG
1.37%
23
RVMD
Revolution Medicines
1.35%
24
BBIO
Bridgebio Pharma
1.34%
25
ROIV
Roivant Sciences Ltd.
1.34%
1–25 of 164
Funds listed by how much of their largest holdings they share with XBI — not a ranking.
Data from SPDR; prices and returns from market data. Page updated October 29, 2026. Holdings and figures change over time. For information only — not investment advice.